Fundraising Fox

Ajax Therapeutics Inc.

New York, US · Founded 2019 · Delaware corporation · 3 known investors

Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery. Its lead candidate, AJ1-11095, is in a Phase 1 clinical trial for patients who have failed currently available Type I JAK2 inhibitors.

AI & Machine LearningBiotechHealthtech

Founders & leadership

Ajax Therapeutics Inc. was founded in 2019 by Martin Vogelbaum.

MV
Martin VogelbaumCo-founder & Board Member
RL
Ross LevineNamed on SEC filing
RF
Ramy FaridNamed on SEC filing

Board

SP
Scott PlatshonBoard directorPartner at EcoR1 Capital

Investors · 3

Inning One Ventures✓ verifiedNew York
EcoR1 CapitalSan Francisco
Vivo CapitalPalo Alto · $10M – $50M

Reported raises · per SEC filings

Form D private placements

$140.4M disclosed across 3 rounds · 2019–2024

▶$95MraisedMay 2024 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin VogelbaumExecutive Officer, Director
  • Ross LevineDirector
  • Scott PlatshonDirector
  • Ramy FaridDirector
Offering amount
$95M
Amount sold
$95M
First sale
Apr 2024
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$37.4MraisedJun 2021 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin VogelbaumExecutive Officer, Director
  • Ross LevineDirector
  • Ramy FaridDirector
  • Scott PlatshonDirector
Offering amount
$40M
Amount sold
$37.4M
First sale
May 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedJun 2019 · 6 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin VogelbaumExecutive Officer, Director
  • Ross LevineDirector
  • Ramy FaridDirector
  • David SchnellDirector
Offering amount
$8M
Amount sold
$8M
First sale
Jun 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Bioworld30 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
AskBio16 shared keywordsAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.

Companies competing with Ajax Therapeutics Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Ajax Therapeutics Inc. do?
Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery. Its lead candidate, AJ1-11095, is in a Phase 1 clinical trial for patients who have failed currently available Type I JAK2 inhibitors.
Who founded Ajax Therapeutics Inc.?
Ajax Therapeutics Inc. was founded by Martin Vogelbaum in 2019.
Who are Ajax Therapeutics Inc.'s investors?
Ajax Therapeutics Inc.'s investors include Inning One Ventures, EcoR1 Capital, Vivo Capital.
How much funding has Ajax Therapeutics Inc. raised?
Ajax Therapeutics Inc. has disclosed $140.4M raised across 3 rounds.
Where is Ajax Therapeutics Inc. headquartered?
Ajax Therapeutics Inc. is headquartered in New York, US.